Glucosamine, a supplement widely used to relieve joint pain, may be linked to a faster progression of Alzheimer’s disease, according to new research from the University of Florida. The study suggests that individuals with mild cognitive impairment who take glucosamine are more likely to develop dementia, and raises concerns about the potential impact of nutritional supplements on those already diagnosed with the disease.
Key takeaways
- Glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia.
- Among patients diagnosed with Alzheimer’s disease and related dementia, glucosamine use was associated with a 25% increased risk of death.
- The researchers point out that glucosamine may be harmful to a brain already affected by neurodegeneration, but is likely safe or protective in cognitively healthy adults.
- The findings highlight the role of metabolic dysfunction in the development of Alzheimer’s disease.
Glucosamine use and dementia risk
The researchers analyzed deidentified health records from the University of Florida Health System, focusing on patients who had been diagnosed with the disease Alzheimer’s disease and associated dementia (ADRD) or mild cognitive impairment (MCI). The study found that approximately 8% of patients in both groups reported taking glucosamine. After taking into account factors such as age and gender, the analysis revealed that glucosamine users with mild cognitive impairment were 25% more likely to develop dementia. Furthermore, among patients diagnosed with ADRD, glucosamine use was associated with a 25% increased risk of death over a 10-year period. Notably, no similar increase in mortality was observed in the MCI group, suggesting that the effects of supplements may vary based on the stage of the disease.
Possible biological mechanisms
The study also explored potential biological explanations for the observed association. Researchers have identified evidence of overactivation of a protein and glucose-limiting pathway in Alzheimer’s disease, which could serve as a new target for treatments. Glucosamine, a molecule that can cross the blood-brain barrier, may interact with these metabolic processes. Experiments on genetically modified mice showed that glucosamine increases the binding of sugar molecules to proteins, exacerbating deficits in social memory. Conversely, reducing glucose-limiting activity improved memory performance in mice. Analysis of human brain tissue from Alzheimer’s patients also revealed significantly higher levels of sugar binding to proteins compared to healthy people.
Implications and future directions
While the findings are observational and require confirmation through clinical trials, they add to growing evidence that metabolic dysfunction plays an important role in neurodegenerative diseases. Experts stress that supplements appear safe or may be protective for cognitively healthy adults, but may be harmful once neurodegeneration begins. The research team plans to conduct further studies, including trials to evaluate whether stopping glucosamine slows cognitive decline in affected individuals and to examine compounds that could disrupt the problematic pathway of sugar labeling. They also intend to investigate whether other supplements that are processed similarly to glucosamine carry similar risks.
